Plus Therapeutics Inc (PSTV)
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing, manufacturing, and commercializing therapies for patients with cancer. Its lead radiotherapeutic candidate is REYOBIQ, a patented treatment being developed for central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company is also developing Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere for solid organ cancers, including primary and secondary liver cancers delivered by intra-arterial injection. In addition, Plus Therapeutics develops laboratory-developed tests such as CNSide Test, which is designed to help identify tumor cells that have spread to the central nervous system in patients with carcinomas and melanomas. Formerly known as Cytori Therapeutics, Inc., the company adopted its current name in July 2019 and is headquartered in Houston, Texas.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PSTV
|
$5.10
|
28.9% Upside
|
Undervalued
|
$36
|
809.1% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 14, 2026
|
-2.3x
|
2.3x
|
5.3x
|
26.362 M
|
13.212 M
|
2.7%
|
93.8%
|
-38.4
|
—
|
182.1%
|
